Clinical trial · Interventional
Laser Treatment of Bladder Tumors in the Outpatient Department
Diode Laser Treatment of Pta Low Grade Bladder Tumors in the Outpatient Department
NCT02659332CI-TRIAL-00020600unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* Primary Objective: To show that small pTa bladder tumors can be removed with diode laser in an outpatient department. * Secondary Objective: To evaluate the patients' symptoms during and after the laser TURBT. * Tertiary Objective: To evaluate the rate of remnant tumor tissue one month after the laser TURBT.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Tumors | Bladder Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TURBT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TURBT
- description
- Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of1ms)
- interventionNames
- Device: TURBT
Primary outcomes (1)
- measure
- Complete Removal by One Laser Treatment (Proportions of patients where the bladder tumors are completely removed by one laser)
- timeFrame
- one month
- description
- Proportions of patients where the bladder tumors are completely removed by one laser treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Recurrence of pTa low grade urothelial bladder tumor * Tumor \< 1.5 cm * \< 6 tumors Exclusion Criteria: * Patients with porphyria * Known hypersensitivity to Hexvix® or porfhyrins * Use of any anticoagulantia * Macroscopic hematuria * Pregnant or breast feeding women * Expected poor compliance * Patients \< 18 years * Patients who do not read or understand Danish
References
Publications (10)
- BACKGROUNDFerlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26. PMID 23485231
- BACKGROUNDSangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU Int. 2005 Jan;95(1):59-63. doi: 10.1111/j.1464-410X.2005.05249.x. PMID 15638895
- BACKGROUNDvan Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009 Sep;56(3):430-42. doi: 10.1016/j.eururo.2009.06.028. Epub 2009 Jun 26. PMID 19576682
- BACKGROUNDJames AC, Gore JL. The costs of non-muscle invasive bladder cancer. Urol Clin North Am. 2013 May;40(2):261-9. doi: 10.1016/j.ucl.2013.01.004. Epub 2013 Feb 13. PMID 23540783
- BACKGROUNDHofstetter A, Frank F, Keiditsch E, Bowering R. Endoscopic Neodymium-YAG laser application for destroying bladder tumors. Eur Urol. 1981;7(5):278-82. doi: 10.1159/000473240. PMID 6894732
- BACKGROUNDDavenport K, Keeley FX Jr, Timoney AG. Audit of safety, efficacy, and cost-effectiveness of local anaesthetic cystodiathermy. Ann R Coll Surg Engl. 2010 Nov;92(8):706-9. doi: 10.1308/003588410X12699663904835. Epub 2010 Jul 2. PMID 20615299
- BACKGROUNDSyed HA, Talbot N, Abbas A, MacDonald D, Jones R, Marr TJ, Rukin NJ. Flexible cystoscopy and Holmium:Yttrium aluminum garnet laser ablation for recurrent nonmuscle invasive bladder carcinoma under local anesthesia. J Endourol. 2013 Jul;27(7):886-91. doi: 10.1089/end.2012.0696. Epub 2013 Jun 22.